- Home
- INM vs PBM Comparison
INM vs PBM Comparison
Compare INM & PBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INM
- PBM
- Stock Information
- Founded
- INM 1981
- PBM 1994
- Country
- INM Canada
- PBM Canada
- Employees
- INM N/A
- PBM N/A
- Industry
- INM Biotechnology: Pharmaceutical Preparations
- PBM
- Sector
- INM Health Care
- PBM
- Exchange
- INM Nasdaq
- PBM NYSE
- Market Cap
- INM 3.2M
- PBM 3.0M
- IPO Year
- INM N/A
- PBM N/A
- Fundamental
- Price
- INM $3.33
- PBM $4.91
- Analyst Decision
- INM
- PBM
- Analyst Count
- INM 0
- PBM 0
- Target Price
- INM N/A
- PBM N/A
- AVG Volume (30 Days)
- INM 9.5M
- PBM 114.1K
- Earning Date
- INM 05-12-2025
- PBM 07-07-2025
- Dividend Yield
- INM N/A
- PBM N/A
- EPS Growth
- INM N/A
- PBM N/A
- EPS
- INM N/A
- PBM 5.24
- Revenue
- INM $4,920,990.00
- PBM N/A
- Revenue This Year
- INM N/A
- PBM N/A
- Revenue Next Year
- INM N/A
- PBM N/A
- P/E Ratio
- INM N/A
- PBM $0.94
- Revenue Growth
- INM N/A
- PBM N/A
- 52 Week Low
- INM $1.72
- PBM $2.93
- 52 Week High
- INM $15.70
- PBM $701.82
- Technical
- Relative Strength Index (RSI)
- INM 59.24
- PBM 53.67
- Support Level
- INM $2.26
- PBM $4.52
- Resistance Level
- INM $5.50
- PBM $5.23
- Average True Range (ATR)
- INM 0.40
- PBM 0.54
- MACD
- INM 0.11
- PBM -0.01
- Stochastic Oscillator
- INM 37.04
- PBM 49.93
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.